Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)

Yulia Vugmeyster, Abhigyan Ravula, Elisabeth Rouits, Roberta Ferretti, Kathrin Glaeser, Christina Esdar,Andreas Schroeder,Andre Koenig,Karthik Venkatakrishnan,Kosalaram Goteti

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用 0|浏览2

暂无评分

关键词

chemoradiotherapy,advanced squamous cell carcinoma,squamous cell carcinoma,iap inhibitor,xevinapant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要